Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis.
dynamic contrast-enhanced MRI
gliomas
lymphoma
meta-analysis
perfusion
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
24
02
2019
revised:
19
05
2019
accepted:
10
06
2019
pubmed:
8
8
2019
medline:
22
8
2020
entrez:
8
8
2019
Statut:
ppublish
Résumé
T1-weighted dynamic contrast-enhanced (DCE) perfusion magnetic resonance imaging (MRI) has been broadly utilized in the evaluation of brain tumors. We aimed at assessing the diagnostic accuracy of DCE-MRI in discriminating between low-grade gliomas (LGGs) and high-grade gliomas (HGGs), between tumor recurrence and treatment-related changes, and between primary central nervous system lymphomas (PCNSLs) and HGGs. We performed this study based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis of Diagnostic Test Accuracy Studies criteria. We systematically surveyed studies evaluating the diagnostic accuracy of DCE-MRI for the aforementioned entities. Meta-analysis was conducted with the use of a random effects model. Twenty-seven studies were included after screening of 2945 possible entries. We categorized the eligible studies into three groups: those utilizing DCE-MRI to differentiate between HGGs and LGGs (14 studies, 546 patients), between recurrence and treatment-related changes (9 studies, 298 patients) and between PCNSLs and HGGs (5 studies, 224 patients). The pooled sensitivity, specificity, and area under the curve for differentiating HGGs from LGGs were 0.93, 0.90, and 0.96, for differentiating tumor relapse from treatment-related changes were 0.88, 0.86, and 0.89, and for differentiating PCNSLs from HGGs were 0.78, 0.81, and 0.86, respectively. Dynamic contrast-enhanced-Magnetic resonance imaging is a promising noninvasive imaging method that has moderate or high accuracy in stratifying gliomas. DCE-MRI shows high diagnostic accuracy in discriminating between HGGs and their low-grade counterparts, and moderate diagnostic accuracy in discriminating recurrent lesions and treatment-related changes as well as PCNSLs and HGGs.
Sections du résumé
BACKGROUND
T1-weighted dynamic contrast-enhanced (DCE) perfusion magnetic resonance imaging (MRI) has been broadly utilized in the evaluation of brain tumors. We aimed at assessing the diagnostic accuracy of DCE-MRI in discriminating between low-grade gliomas (LGGs) and high-grade gliomas (HGGs), between tumor recurrence and treatment-related changes, and between primary central nervous system lymphomas (PCNSLs) and HGGs.
METHODS
We performed this study based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis of Diagnostic Test Accuracy Studies criteria. We systematically surveyed studies evaluating the diagnostic accuracy of DCE-MRI for the aforementioned entities. Meta-analysis was conducted with the use of a random effects model.
RESULTS
Twenty-seven studies were included after screening of 2945 possible entries. We categorized the eligible studies into three groups: those utilizing DCE-MRI to differentiate between HGGs and LGGs (14 studies, 546 patients), between recurrence and treatment-related changes (9 studies, 298 patients) and between PCNSLs and HGGs (5 studies, 224 patients). The pooled sensitivity, specificity, and area under the curve for differentiating HGGs from LGGs were 0.93, 0.90, and 0.96, for differentiating tumor relapse from treatment-related changes were 0.88, 0.86, and 0.89, and for differentiating PCNSLs from HGGs were 0.78, 0.81, and 0.86, respectively.
CONCLUSIONS
Dynamic contrast-enhanced-Magnetic resonance imaging is a promising noninvasive imaging method that has moderate or high accuracy in stratifying gliomas. DCE-MRI shows high diagnostic accuracy in discriminating between HGGs and their low-grade counterparts, and moderate diagnostic accuracy in discriminating recurrent lesions and treatment-related changes as well as PCNSLs and HGGs.
Identifiants
pubmed: 31389669
doi: 10.1002/cam4.2369
pmc: PMC6745862
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5564-5573Subventions
Organisme : The National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (UCLH BRC)
ID : BRC345/NS/SB/101410
Pays : International
Organisme : The NIHR Collaboration for Leadership in Applied Health Research and Care North Thames at Bart's Health NHS Trust (NIHR CLAHRC North Thames)
Pays : International
Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Neuroimaging. 2016 May;26(3):366-71
pubmed: 26707628
J Clin Neurosci. 2012 Jun;19(6):820-3
pubmed: 22381582
Eur J Radiol. 2016 Jun;85(6):1147-56
pubmed: 27161065
AJNR Am J Neuroradiol. 2017 Mar;38(3):485-491
pubmed: 27932505
J Magn Reson Imaging. 2006 Apr;23(4):554-63
pubmed: 16506143
AJNR Am J Neuroradiol. 2014 Aug;35(8):1503-8
pubmed: 24722313
Acad Radiol. 2018 Mar;25(3):338-348
pubmed: 29223713
Eur Radiol. 2017 Apr;27(4):1344-1351
pubmed: 27436023
AJR Am J Roentgenol. 2013 Jan;200(1):24-34
pubmed: 23255738
Cancer Med. 2019 Sep;8(12):5564-5573
pubmed: 31389669
AJNR Am J Neuroradiol. 2013 Dec;34(12):2278-86
pubmed: 23828115
J Clin Epidemiol. 2005 Sep;58(9):882-93
pubmed: 16085191
Radiology. 2014 Sep;272(3):843-50
pubmed: 24814181
CMAJ. 2007 Apr 10;176(8):1091-6
pubmed: 17420491
Neuro Oncol. 2011 Sep;13(9):1037-46
pubmed: 21803763
J Neurol Sci. 2017 Feb 15;373:9-15
pubmed: 28131237
AJNR Am J Neuroradiol. 2012 Sep;33(8):1539-45
pubmed: 22442046
Radiology. 2013 Nov;269(2):561-8
pubmed: 23878286
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
J Neurooncol. 2015 Oct;125(1):183-90
pubmed: 26275367
Clin Radiol. 2015 Oct;70(10):1128-35
pubmed: 26152879
Nat Rev Clin Oncol. 2009 Nov;6(11):648-57
pubmed: 19806145
PLoS One. 2015 Sep 18;10(9):e0138573
pubmed: 26384329
Eur J Radiol. 2016 Oct;85(10):1722-1727
pubmed: 27666608
Neuroradiology. 2007 Oct;49(10):795-803
pubmed: 17619871
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
PLoS One. 2017 Mar 16;12(3):e0173430
pubmed: 28301491
Clin Radiol. 2014 Jun;69(6):e264-72
pubmed: 24594379
Radiology. 2015 Mar;274(3):830-40
pubmed: 25333475
AJNR Am J Neuroradiol. 2015 Nov;36(11):2017-22
pubmed: 26228886
AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87
pubmed: 16551981
Br J Radiol. 2018 Dec;91(1092):20170930
pubmed: 29902076
Eur Radiol. 2017 Oct;27(10):4129-4144
pubmed: 28332014
Neuro Oncol. 2017 Jan;19(1):118-127
pubmed: 27502247
Surg Neurol. 1998 Apr;49(4):436-40
pubmed: 9537664
Neuroradiology. 2013 Feb;55(3):361-9
pubmed: 23262559
Radiology. 2007 May;243(2):539-50
pubmed: 17456876
Magn Reson Imaging. 2000 Dec;18(10):1201-14
pubmed: 11167040
J Magn Reson Imaging. 2011 Feb;33(2):296-305
pubmed: 21274970
Br J Haematol. 2016 Aug;174(3):417-24
pubmed: 27018254
AJNR Am J Neuroradiol. 2000 May;21(5):891-9
pubmed: 10815665
Neuroradiology. 2013 May;55(5):603-13
pubmed: 23377234
J Neuroimaging. 2015 Sep-Oct;25(5):792-8
pubmed: 25867683
Acad Radiol. 2013 Dec;20(12):1557-65
pubmed: 24200483
Cancer Imaging. 2015 Mar 21;15:4
pubmed: 25889239
AJNR Am J Neuroradiol. 2015 Apr;36(4):686-93
pubmed: 25500312
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acad Radiol. 2011 May;18(5):575-83
pubmed: 21419671
J Clin Neurosci. 2013 Aug;20(8):1110-3
pubmed: 23673143
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
AJNR Am J Neuroradiol. 2014 Jun;35(6):1103-10
pubmed: 24384119
Science. 1988 Jun 3;240(4857):1285-93
pubmed: 3287615
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Comput Assist Tomogr. 2013 May-Jun;37(3):321-6
pubmed: 23673999